Alexion Pharmaceuticals Inc (ALXN)

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. It offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma sebelipase alfa for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 Intravenous, which is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 Subcutaneous, which is in Phase III clinical trials for PNH and aHUS; ALXN1820, which is in Phase I clinical trial as a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840, which is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which is in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for the treatment of relapsed/refractory chronic lymphocytic leukemia. It serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has a collaboration and license agreement with Neurimmune AG, Dicerna, Merck, and Zealand Pharma. The company was incorporated in 1992 and is based in Boston, Massachusetts, with an additional office in Baar, Switzerland. As of July 21, 2021, Alexion Pharmaceuticals, Inc. operates as a subsidiary of AstraZeneca PLC.